Affiliation:
1. Health System Strengthening, APIN Public Health Initiatives, Abeokuta, Ogun State, Nigeria
2. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
3. Department of Pharmacology & Therapeutics, Makerere University, Kampala, Uganda
Abstract
Objectives To determine alignment between national and World Health Organization (WHO) treatment recommendations, medicines prioritisation in country's essential medicines list (EML), and medicines availability in National drug register. Design An audit of medicines for malaria, tuberculosis, hypertension and type 2 diabetes mellitus listed in the national standard treatment guidelines (STGs) of Kenya, Tanzania and Uganda, as of March 2021, against WHO treatment guidelines, and respective country EML and National drug register. Setting Not applicable. Participants None. Main outcome measures Proportion of medicine in country's STGs that align with WHO treatment recommendations, country's EML and country's drug register. Results Some disease areas had two sets of treatment guidelines – national STGs and disease-specific treatment guidelines (DSGs) developed at different times with different recommended medicines. Both STGs and DSGs included medicines not recommended by the WHO or not listed on the country EML and drug register. Non-WHO-recommended medicines accounted for 17/68 (25%), 10/57 (18%) and 3/30 (10%) of all STG medicines in Kenya, Tanzania and Uganda, respectively. For tuberculosis, the numbers and proportion of STG medicines listed on the respective national EMLs were 2/6 (33%), 15/19 (79%) and 4/5 (80%) in Kenya, Tanzania and Uganda. All tuberculosis medicines included in Kenya's and Uganda's STGs were registered compared with only 12/19 (63%) tuberculosis medicines in Tanzania's STG. Conclusions Alignment between treatment guidelines, EMLs and drug registers is crucial for effective national pharmaceutical policy. Research is needed to understand the inclusion of medicines on STGs and DSGs which fall outside WHO treatment guidelines; the non-alignment of some STGs and DSGs, and STGs and DSGs including medicines which are not on country EML and drug register.
Reference44 articles.
1. Management Sciences for Health and World Health Organization. Drug and Therapeutics Committee Training Course: Session 10. Standard Treatment Guidelines Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Arlington, VA, 2007. Available from: https://www.who.int/medicines/technical_briefing/tbs/10-PG_Standard-Treatment-Guidelines_final-08.pdf.
2. World Health Organisation. Country pharmaceutical situations: Fact Book on WHO Level 1 indicators 2007, 2007. Available from: https://www.who.int/medicines/technical_briefing/tbs/WHO_EMP_MPC_2010_1full.pdf.
3. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
4. Registration of antimicrobials, Kenya, Uganda and United Republic of Tanzania, 2018